




PARIS
INTERNATIONAL
LIVER MEETING

SCIENTIFIC PROGRAM 2026

Maison de la Chimie, Paris
January 19-21, 2026

1st annual meeting

With the scientific support of



parislivermeeting.com

Welcome to the Paris International Liver Meeting 2026!

Dear Colleagues,

It is our great pleasure to welcome you on behalf of the Scientific Committee to the Paris International Liver Meeting, which will be held in the beautiful city of Paris from January 19-21, 2026.

This meeting will bring together leading experts, clinicians, researchers, biopharmaceutical industry and healthcare professionals from around the world to share the latest clinically relevant advances in the management and treatment of chronic liver diseases. Also, this meeting will bring together all important stakeholders to interact and share practical perspectives about important liver diseases.

Over three days, the program will explore and provide up-to-date short reviews by the best experts on the different aspects of clinical hepatology, including MASLD, MetALD, ALD, viral hepatitis, cholestatic liver diseases, HCC and complications of cirrhosis.

Over the course of the meeting, you will have the opportunity to interact with thought leaders, attend thought-provoking sessions, contribute to discussions and interact with leading biopharmaceutical leaders in liver disease that we hope will not only deepen your knowledge, but also be helpful in your clinical practice.

Join us at the prestigious Maison de la Chimie for a fruitful and productive meeting!

Laurent Castera, MD PhD

Zobair M. Younossi, MD

Co-Chairs, Paris International Liver Meeting





MONDAY, 19 JANUARY - MORNING

08:30 - 08:50 AM WELCOME DESK OPENING

08:50 - 09:00 AM INTRODUCTION

Laurent Castera (FR) & Zobair Younossi (US)

09:00 - 10:30 AM SESSION 1: Hepatitis B – D Optimal Management

Chairs: Pietro Lampertico (IT) & Sabela Lens (ES)

09:00-09:15 **EASL/AASLD 2025 HBV guidelines** Markus Cornberg (DE)

09:15-09:30 **HDV new insights from virology to epidemiology and natural history**
Maurizia Brunetto (IT)

09:30-09:45 **HDV therapy: BLV monotherapy and combination** Tarik Asselah (FR)

09:45-10:00 **HDV therapy: new antiviral therapies (phase 2 studies)**
Pietro Lampertico (IT)

10:00-10:30 **Panel discussion** (Moderator Sabela Lens)

10:30 - 11:00 AM COFFEE BREAK

11:00 - 12:30 PM SESSION 2: Advances in the Management of Cirrhosis Complications

Chairs: Annalisa Berzigotti (CH) & Adrian Gadano (AR)

11:00-11:15 **What new evidence and definitions have been further developed with Baveno VII and beyond** Annalisa Berzigotti (CH)

11:15-11:30 **Transjugular intrahepatic porto-systemic shunt (TIPS): Expanding Indications and Refining Risk Stratification** Dominique Thabut (FR)

11:30-11:45 **Acute Kidney Injury in Cirrhosis: an update from the ADQI and International Club of Ascites (ICA) Consensus** Claire Francoz (FR)

11:45-12:00 **New challenges in SBP prophylaxis: Beyond the guidelines**
Paolo Angeli (IT)

12:00-12:30 **Panel Discussion** (Moderator Adrian Gadano)

12:30 - 01:30 PM LUNCH SYMPOSIUM

01:30- 02:00 PM COFFEE / DESSERTS



MONDAY, 19 JANUARY - AFTERNOON

02:00 - 02:30 PM STATE OF THE ART LECTURE

Chair : Lawrence Serfaty (FR)

Fibrosis in MASH: A Surrogate for Mortality and Endpoint for Treatment

Massimo Pinzani (IT)

02:30 - 04:00 PM SESSION 3: Advances in the Management of HCC

Chairs: Josep Llovet (ES-US) & Massimo Pinzani (IT)

02:30-02:45 Overview of Guidelines of HCC management (EASL, AASLD, ESMO)

Josep M Llovet (ES-US)

02:45-03:00 Advances in the management of early/intermediate HCC

Riccardo Lencioni (IT)

03:00-03:15 Advances in the management of advanced HCC

Lorenza Rimassa (IT)

03:15-03:30 Emerging therapies

David Pinato (UK)

03:30-04:00 Panel discussion (moderator Massimo Pinzani)

04:00 - 04:30 PM COFFEE BREAK

04:30 - 05:30 PM WORKSHOPS

1 - How do I use new HBV markers in practice?

Jean-Michel Pawlotsky (FR) & Alessio Aghemo (IT)

2 - How do I manage and treat HDV in my practice?

Fabien Zoulim (FR) & Maria Buti (GE)

3 - When should I consider liver transplantation in a patient with HCC?

François Durand (FR) & Jean- François Dufour (CH)

4 - MASLD and viral hepatitis (hepatitis B & C): is there an impact?

George Papatheodoridis (GR) & Yusuf Yilmaz (TR)

5 - How do I use NITs for treatment of MASH in 2026?

Vlad Ratziu (FR) & Vincent Wong (HK)

05:30 PM

CONCLUSION DAY 1

Laurent Castera (FR) & Zobair Younossi (US)



TUESDAY, 20 JANUARY - MORNING

08:30 - 09:30 AM WORKSHOPS

1 - Management of pruritus and fatigue for patients with PBC

Andreas Kremer (CH) & Ana Lleo (IT)

2 - How do I diagnose and manage portal hypertension in my clinic?

Pierre-Emmanuel Rautou (FR) & Thomas Reiberger (AT)

3 - What are the tips to implement diet and physical exercise in my practice?

Sébastien Czernichow (FR) & Shira Zelber-Sagi (IL)

4 - How to accurately estimate alcohol consumption over time in clinical practice?

Sven Francque (BE) & Christophe Moreno (BE)

5 - What are my preferred drugs to treat obesity or type 2 diabetes in a patient with MASLD?

Cyrielle Caussy (FR) & Jean-François Gautier (FR)

09:30 - 11:00 AM SESSION 4: MASLD Epidemiology, Economic Impact, and Risk Stratification Using NITs

Chairs: Manolis Tsochatzis (UK) & Laurent Castera (FR)

09:30-09:45 **Epidemiology and financial impact of MASH** Zobair Younossi (US)

09:45-10:00 **NIT algorithms for identifying high risk patients with MASH**

Jérôme Boursier (FR)

10:00-10:15 **Non-invasive tests for treatment response in MASH**

Manolis Tsochatzis (UK)

10:15-10:30 **Pulling it all together: the use of NITs in clinical practice of MASH**

Vincent Wong (HK)

10:30-11:00 **Panel discussion** (moderator Laurent Castera)

11:00 - 11:30 AM COFFEE BREAK



TUESDAY, 20 JANUARY - AFTERNOON

11:30 - 12:55 PM SESSION 5: MASLD Treatment

Chairs: Mazen Nouredin (US) & Vincent Wong (HK)

- | | |
|-------------|---|
| 11:30-11:45 | Lifestyle modifications for patients with MASH Shira Zelber-Sagi (IL) |
| 11:45-12:00 | Treatment of MASH-Co Morbidities (type 2 diabetes)
Elisabetta Bugianesi (IT) |
| 12:00-12:15 | Current treatment of MASH Mazen Nouredin (US) |
| 12:15-12:30 | Future treatments of MASH: What is in the pipeline? Frank Tacke (DE) |
| 12:30-12:55 | Panel Discussion (moderator Vincent Wong, Michael Betel
patient representative) |

01:00 - 02:00 PM LUNCH SYMPOSIUM

02:00 - 02:30 PM COFFEE / DESSERTS

02:30 - 03:00 PM STATE OF THE ART
Advances in hepatic encephalopathy
Debbie Shawcross (UK)

03:00 - 04:00 PM SYMPOSIUM

04:00 - 04:30 PM COFFEE BREAK

04:30 - 06:00 PM SESSION 6: MetALD and ALD
Chairs: Maja Thiele (DK) & Christophe Moreno (BE)

- | | |
|-------------|--|
| 04:30-04:45 | Update on diagnosis of MetALD Maja Thiele (DK) |
| 04:45-05:00 | The natural history of MetALD Hannes Hagström (SE) |
| 05:00-05:15 | Update on ALD Ramon Bataller (ES) |
| 05:15-05:30 | Pharmaceutical and non-pharmaceutical treatment for MetALD and ALD Mark Thursz (UK) |
| 05:30-06:00 | Panel discussion (Christophe Moreno moderator) |

06:00 PM CONCLUSION DAY 2
Laurent Castera (FR) & Zobair Younossi (US)



WEDNESDAY, 21 JANUARY - MORNING

09:00 - 10:00 PM **SESSION 7: R&D - The drug pipelines presented by sponsors (10 min each)**

Chairs: Laurent Castera (FR) & Zobair Younossi (US)

10:00 - 10:15 AM **COFFEE BREAK**

10:15 - 11:30 AM **SESSION 8: Current Optimal treatment and Future Innovations in PBC and PSC**

Chairs: Andreas Kremer (CH) & Ana Lleo (IT)

10:15-10:30 **How to treat and assess risk in a patient with PBC?** David Jones (UK)

10:30-10:45 **How to treat and monitor a patient with PSC?** Andreas Kremer (CH)

10:45-11:00 **Future treatment for PBC and PSC** Ana Lleo (IT)

11:00-11:30 **Panel Discussion**

11:30 - 12:00 PM **SPECIAL LECTURE**

Screening for liver disease in the general population: the LiverScreen Story Pere Gines (ES)

12:00 PM **CONCLUSION DAY 3**

Laurent Castera (FR) & Zobair Younossi (US)



PARIS
INTERNATIONAL
LIVER MEETING

Co-Chairs



Laurent CASTERA, MD, PhD
FRANCE

Professor of Hepatology, Head of the NASH/MASH Program
Department of Hepatology, Hôpital Beaujon, AP-HP
INSERM UMR 1149, Centre de Recherche sur l'Inflammation Paris Montmartre,
Université Paris-Cité, Clichy, France



Zobair M YOUNOSSI, MD, MPH
USA

Chairman of the Global NASH/MASH Council, Washington DC, USA
Professor and Chairman of Beatty Liver and Obesity Research, Inova Health System,
Falls Church, VA, USA





**PARIS
INTERNATIONAL
LIVER MEETING**

Scientific Committee



Annalisa BERZIGOTTI, MD, PhD
SWITZERLAND

Full Professor of Clinical Hepatology at the University of Berne and Chief of Hepatology and Co-Director of the Department of Visceral Surgery and Medicine of the Inselspital, University Hospital of Berne



Adrian GADANO, MD, PhD
ARGENTINA

Head of the Research Department at the Hospital Italiano de Buenos Aires



Andreas KREMER, MD, PhD
SWITZERLAND

Head of Hepatology and Vice Director of the Department of Gastroenterology and Hepatology, University Hospital Zurich



Pietro LAMPERTICO, MD, PhD
ITALY

Full Professor in the Gastroenterology, Director of the Gastroenterology and Hepatology Division, Head of the "A. M. e A. Migliavacca" Center for Liver Disease at the Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, University of Milan



Josep LLOVET, MD, PhD
SPAIN

Full Professor of Medicine and Director of the Liver Cancer Program at Icahn School of Medicine at Mount Sinai (New York - USA)
ICREA Research Prof at IDIBAPS-Hospital Clínic and Full Prof of Medicine-Hepatic Oncology at the Univ. of Barcelona



Mazen NOUREDDIN, MD, MHSc
USA

Professor of Medicine at the Lynda K. and David M. Underwood Center for Digestive Disorders J.C. Walter Jr. Transplant Center Sherrie & Alan Conover Center for Liver Disease & Transplantation at Houston Methodist Hospital



Massimo PINZANI, MD, PhD
ITALY

Emeritus Professor of Medicine at University College London (UCL) (UK)
Scientific Director of UPMC (University of Pittsburgh Medical Center)-ISMETT IRCSS in Palermo



Maja THIELE, MD, PhD
DENMARK

Professor of Hepatology at Department of Gastroenterology and Hepatology, Odense University Hospital and University of Southern Denmark



Manolis TSOCHATZIS, MD, MSc
UNITED KINGDOM

Professor of Hepatology and Consultant Hepatologist at the UCL Institute for Liver and Digestive Health, Royal Free Hospital in London



Vincent WONG, MD
HONG KONG

Mok Hing Yiu Professor of Medicine and head of the Division of Gastroenterology and Hepatology at The Chinese University of Hong Kong

FACULTY

AGHEMO Alessio

ANGELI Paolo

ASSELAH Tarik

BATALLER Ramon

BERZIGOTTI Annalisa

BETEL Michael

BOURSIER Jérôme

BRUNETTO Maurizia

BUGIANESI Elisabetta

BUTI Maria

CASTERA Laurent

CAUSSY Cyrielle

CZERNICHOW Sébastien

CORNBURG Markus

DUFOUR Jean-François

DURAND François

FRANCOZ Claire

FRANCQUE Sven

GADANO Adrian

GAUTIER Jean-François

GINES Pere

HAGSTRÖM Hannes

JONES David

KREMER Andreas

LAMPERTICO Pietro

LENCIONI Riccardo

LENS GARCÍA Sabela

LLEO Ana

LLOVET Josep

MORENO Christophe

NOUREDDIN Mazen

PAPATHEODIRIS George

PAWLOTSKY Jean-Michel

PINATO David

PINZANI Massimo

RATZIU Vlad

RAUTOU Pierre-Emmanuel

REIBERGER Thomas

RIMASSA Lorenza

SERFATY Lawrence

SHAWCROSS Debbie

TACKE Frank

THABUT Dominique

THIELE Maja

THURSZ Markus

TSOCHATZIS Manolis

WONG Vincent

YILMAZ Yusuf

YOUNOSSI Zobair

ZELBER SAGI Shira

ZOULIM Fabien